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Abstract
Zinc is a mineral that plays a vital role in many biological processes and plays an important role in insulin action
and carbohydrate metabolism. It may also have a protective role in the prevention of atherogenesis. Numerous
studies have evaluated the effects of Zinc supplementation on serum lipids in humans and have demonstrated
varying results. We systematically evaluated the literature and performed a meta-analysis on the effects of Zinc
supplementation on serum lipids. A five staged comprehensive search of the literature was conducted in the
following databases; PubMed, Web of Science and SciVerse Scopus for studies published before 31st December
2014. All controlled clinical trial in humans, that included a Zinc supplement intervention, either alone or in
combination with other micronutrients and evaluated effects on serum lipids (total cholesterol [TC], triglycerides [TG],
LDL cholesterol [LDL-c] and HDL cholesterol [HDL-c]). A meta-analysis of selected studies was performed using RevMan
v5.3. The Jaded scale was used to assess the methodological quality of the trials included in the systematic review. A
total of 24 studies were included in Meta analysis, which included a total of 33 Zinc interventions, in a total of 14,515
participants in the Zinc intervention or control group. The duration of Zinc supplementation ranged from 1 month
to 7.5 years. The dose of elemental Zinc supplemented ranged from 15–240 mg/day. The pooled mean
difference for TC between Zinc supplemented and placebo groups from random effects analysis was −10.92 mg/dl
(95 % CI: −15.33, −6.52; p < 0.0001, I2 = 83 %), while for HDL cholesterol it was 2.12 mg/dl (95 % CI: −0.74, 4.98; p = 0.15,
I2 = 83 %). The pooled mean difference for LDL-c between Zinc supplemented and placebo group from random effect
analysis was −6.87 mg/dl (95 % CI: −11.16,-2.58; p < 0.001, I2 = 31) and for TG it was −10.92 mg/dl (95 % CI: −18.56, − 3.28;
p < 0.01, I2 = 69 %). In conclusion, Zinc supplementation has favourable effects on plasma lipid parameters. Zinc
supplementation significantly reduced total cholesterol, LDL cholesterol and triglycerides. Therefore it may have
the potential to reduce the incidence of atherosclerosis related morbidity and mortality.
Introduction
Zinc is a mineral that plays a vital role in many bio-
logical processes, such as enzyme action, cell membrane
stabilization, gene expression and cell signaling [1]. It is
required for structural and functional integrity of more
than 2000 transcription factors and 300 enzymes; hence,
almost all metabolic pathways are in some ways reliant
on at least one Zinc requiring protein [2, 3]. Zinc also
plays an important role in insulin action and carbohydrate
metabolism [4]. Studies have shown that diabetes is
accompanied by hypozincemia and hyperzincuria [5, 6]. In
addition Zinc is also an integral part of key anti-oxidant
enzymes and Zinc deficiency impairs their synthesis,
resulting in increased oxidative stress [7].
Zinc deficiency is known to affect 1/3rd of the world’s
population [8]. It is estimated that Zinc deficiency is a
major factor contributing to 1.4 % of deaths worldwide
[8]. Zinc deficiency is more common in developing
countries, and although severe deficiency is rare in de-
veloped countries, marginal deficiency is thought to be
relatively common [9, 10]. Zinc deficiency is associated
with many diseases, including malabsorption syndrome,
chronic liver disease, chronic renal disease, sickle cell
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disease, diabetes and malignancy [11]. Animal studies
have shown that Zinc deficiency has profound effects on
the cell structure of the aorta, fatty acid metabolism and
carbohydrate metabolism, being disadvantageous for
maintaining vascular health [12]. Zinc deficiency renders
vascular endothelial cells more susceptible to the effects of
oxidative stress [13, 14]. Furthermore, in LDL receptor
knock-out mice acute Zinc deficiency elicits changes in
key transcription factors and adhesion molecules that are
pro-atherogenic [15]. In human studies a strong negative
association was observed between the dietary intake of
Zinc and the incidence of diabetes and heart disease,
as well as several of their associated risk factors in-
cluding hypertension and hyper-triglyceridemia [16].
Hence Zinc may have a protective role in the prevention
of atherogenesis [12].
Several human studies have demonstrated that Zinc
supplementation reduces total cholesterol, LDL choles-
terol and triglycerides, in addition to increasing the HDL
cholesterol levels [17–20]. However, these results have
been contradicted by other studies [21–23]. Even under
the most rigorous study design conditions, a single well-
planned study rarely provides definitive results [24]. Hence,
changing clinical practices relying on a single high-profile
clinical trial can be harmful to patients' health. Systematic
reviews and meta-analyses on the other hand often have
increased power and decreased bias as compared with
the individual studies they include, and the careful pooling
of treatment effects can provide the most accurate overall
assessment of an intervention [24]. In 2008 Foster et al.
performed a meta-analysis of controlled clinical trials
to determine the effect of Zinc supplementation on
serum lipids in humans [25]. They did not observe any
beneficial effect of Zinc supplementation on plasma li-
poproteins in the overall analysis, whilst in sub group
analysis of healthy subjects Zinc supplementation was
associated with a reduction in HDL cholesterol concen-
trations [25]. However, since then several recent studies
have evaluated the effects of Zinc supplementation on
serum lipids in humans and have demonstrated varying
results [17, 21–23, 25–28]. Hence the present study
aims to re-explore the area under discussion, by sys-
tematically evaluating the literature and performing an
up to date meta-analysis on the effects of Zinc supple-
mentation on serum lipids: total cholesterol (TC); LDL
cholesterol (LDL-c); HDL cholesterol (HDL-c); and tri-
glycerides (TG) in humans.
Methods
The current systematic review was conducted in accord-
ance with the PRISMA statement (Preferred Reporting
Items for Systematic reviews and Meta-Analyses) for
systematic reviews of interventional studies [29].
Literature search
A five staged comprehensive search of the literature was
conducted in the following databases; PubMed® (U.S.
National Library of Medicine, USA), Web of Science®
[v.5.4] (Thomson Reuters, USA) and SciVerse Scopus®
(Elsevier Properties S.A, USA) for studies published
before 31st December 2014. During the first stage the
above databases were searched using the following
keywords; (‘Zinc’ or ‘Zn’ or ‘Zinc supplementation’ or
‘Zn supplementation’ or ‘Zinc therapy’ or ‘Zn therapy’)
AND (‘Lipid(s)’or ‘Cholesterol’ or ‘LDL’ or ‘HDL’ or
‘Lipoprotein(s)’ or ‘Triglyceride(s)’).
In the second stage the total hits from the 3 databases
were pooled and duplicates were removed. This was
followed by screening of the retrieved articles by reading
the article ‘title’ in the third stage and ‘abstracts’ in
stage four. In the fifth stage individual manuscripts
were screened, and those not satisfying inclusion criteria
were excluded. To obtain additional data a manual search
of the reference lists of articles selected in stage five was
performed. This search process was conducted independ-
ently by two reviewers (PR and RJ) and the final group of
articles to be included in the review was determined after
an iterative consensus process.
Inclusion and exclusion criteria
A study was considered eligible for data extraction if it
was a controlled clinical trial in humans, that included a
Zinc supplement intervention, either alone or in com-
bination with other micronutrients and evaluated at least
one of the following outcomes: TG,TC, LDL-c and HDL-c.
Results were limited to studies conducted in humans,
published in English, while conference proceedings, ed-
itorials, commentaries and book chapters/book reviews
were excluded.
Data extraction and analysis
A meta-analysis of selected studies examining the effects
of Zinc supplementation on serum lipid parameters
was performed using the Rev Man version 5.3 (Review
Manager, Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2011) statistical software
package. A random effect analysis was conducted for
all comparisons and in all analyses a p-value < 0.05
was considered statistically significant. Forest plots
were used to illustrate the study findings and meta-
analysis results. Statistical heterogeneity was assessed
using the χ2 test on Cochrane’s Q statistic [30] and by
calculating I2 [31] and is considered significant if p < 0.05.
TC, LDL-c, HDL-c and TG are reported as mg/dl, where
studies reported as mmol/l a numerical conversion to
mg/dl was done as follows; For TC, HDL-c, and LDL-c
cholesterol, values presented in mmol/l multiplied by con-
version factor 38.67 and for TG, conversion factor used
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was 88.57 [32]. In a study where there was several in-
terventions including interventions with multiple supple-
ments, the interventions using Zinc supplementation alone
was used in the meta analysis as the elemental dose of Zinc
was similar in all interventions [33]. In a study done
by Farvid et al. intervention with least number of additional
supplements was used to compare with the placebo group
[34]. In cross-over studies the pooled estimate of Zinc
and placebo groups after completion of entire cross-
over scheme was used in the analysis [17, 19, 35]. Three
separate sub-group analyses were performed; a) for
group of studies using Zinc supplementation alone
[17–19, 21–23, 26, 27, 33, 35–43], b) for group of studies
done on healthy participants [35–37, 39–41, 44] and c)
for group of studies done on non-healthy participants
[17–23, 26–28, 33–35, 38, 42, 43, 45, 46].
Quality assessment
The Jaded scale was used to assess the methodological
quality of the trials included in the systematic review
[47]. Each study was scored from 0 (‘poor’ quality) to 5
(‘good’ quality) according to the following criteria: 1)
was the study described as randomized? ;2) was the study
described as double blind?; 3) was there a description
of withdrawals and dropouts? 3) was the method of
randomization described in the paper and appropriate?; 4)
was the method of blinding described and appropriate?.
Each question would score a single point if the answer is
‘yes’ or zero points if the answer is ‘no’. Questions 4) and 5)
would score −1 mark each if method of randomization was
described, but inappropriate and method of blinding was
described, but inappropriate respectively.
Results
Literature search
Literature search was done according to the above
search criteria and the search strategy is summarized in
Fig. 1. The number of articles identified initially from
the different databases were as follows; PubMed (n =
995), Web of Science (n = 802), SciVerse Scopus (n =
549). Five additional articles were identified by manual
searching the reference lists of included studies. After
removal of duplicates and screening of studies by read-
ing the title, abstract and finally the full text, 32 studies
were eligible to be included in systematic review. De-
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Fig. 1 Summarized search strategy
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Reduction in TG, TC and LDL
Age-Related Eye Disease
Study Research Group [48]
2002; United States
R, DB, P 5 years 166 202 (Zn),168
(Zn + antioxidants)
181 (antioxidants)




ZnO 80 mg/day TG, TC, HDL-c,
LDL-c
Lipid profile not significantly
affected by long-term
supplementation with Zinc
Black et al. [36] 1988;
United States
R, DB, P 3 months 9 13,9 Males 19-29 Healthy Zn gluconate
50 mg/day




Serum TC, VLDL, LDL-c, TG
not affected. Both Zn groups
had significantly lower HDL
than placebo group and lower
than baseline
Bogden et al. [37] 1988;
United States
R, DB, P 3 months 36 36, 31 Both 60-89 Healthy Zn acetate
15 mg/day
(n = 36) 100 mg/day
(n = 31)
TC, HLD-c, Serum TC and HDL-c was not
altered significantly by Zinc
Boukaïba et al. [35] 1993;
France








Reduced TC in both Lean and
Reference groups than placebo.
Reduced HDL in Reference group.
Higher TG in Lean group. No effect
on TG in Reference group. Ratio of
LDL-c to HDL-c not affected.
23, 21
Lean – BMI < 21
kg/m2 (n = 21)
Brewer et al. [49] 1991;
United States
O 1-5 years No controls Both NM Wilson’s disease NM TG, TC, HDL-c, HDL level reduced in males only.
TC reduced in both genders.
LDL-c, TC/HDL-c11(F), 13(M)
Chevalier et al. [38] 2002;
United States





Crouse et al. [39] 1984;
United States
R, DB, P 2 months 10,11 Males 20-55 Healthy ZnSO4 TG, TC, HDL-c, No significant change in lipid
parameters in both groups




Sedentary (n = 23)
Farvid et al. [34] 2004; Iran R, DB, P 3 months 18 Both 30-69 Type-2 ZnSO4 TG, TC, HDL-c, Co-supplementation of Mg, Zn,
Vitamins C and E significantly
increases HDL-c. TG, TC, LDL-c
not altered
Diabetes patients 30 mg/day LDL-c16 (Zn +Mg), 17
(Zn + Mg + Vit.C + Vit.E)
18 (Vit C+ Vit.E)
Federico et al. [45] 2001;
Italy
R, CC 2 months 30 Both 46-61 Gut cancer
patients













Table 1 Description of included studies (Continued)
21 mg/day30 (Zn + Se)
Feillet-Coudray et al. [40]
2006; France
R, DB, P 6 months 16 (F),16 (M),
16 (F), 16 (M)
Both 55-70 Healthy Zn gluconate TG, TC, HDL-c, No significant change in lipid
parameters
16 (F), 16 (M),
15 (F), 16 (M)
LDL-c15 mg/day(n = 32)
30 mg/day(n = 31)
Foster et al. [33] 2013;
Australia
R, DB, P 3 months 10 Females 65.0 ±
7.8
Type-2 Zn sulphate TG, TC, HDL-c, No significant change in lipid
parameters
Diabetes patients 40 mg/day LDL-c12 (Zn), 11 (Zn + ALA)
10 (ALA)
Freeland-Graves et al. [50]
1982; United States
R, DB, P 2 months 8 Females 18-40 Healthy Zn Acetate HDL-c A transient non-dose related
reduction in HDL-c
15 mg/day (n = 8)
8, 8, 8 50 mg/day (n = 8)
100 mg/day (n = 8)
Gatto and Samman [51]
1995; Australia
R, B, C 1 month 10 Males 24.3 ±
4.2
Healthy ZnSO4 TG, TC, No significant changes in TC,
LDL-c or TG. HDL2:HDL3 ratio
increased10 50 mg/day HDL-c,
LDL-c
Gunasekara et al. [46] 2011;
Sri Lanka
R, B, P 4 months 32 Both M-54.6
± 7.0
Type-2 ZnSO4 TG, TC, HDL-c, Reduced TC, LDL and TC/HDL-c








R, DB, C 2 months 60 Both 6-10 Obese ZnSO4 TG, TC, HDL-c, TC, LDL-c and TG reduced. No
change in HDL-c
20 mg/day LDL-c60
Hercberg et al. [44]
2005; France
R, DB, P 7.5 years 3869 (F), 2508(M) Both 35-60 Healthy Multi-vitamin TG, TC, HDL-c, Significant reduction of HDL-c
in men. No significant change
in other lipid parameters3844 (F), 2520(M) (Zn 20 mg/day) LDL-c
Hininger-Favier et al. [41]
2007; Europe
R, DB, P 6 months 130 Both 55-85 Healthy Zn Gluconate TG, TC, HDL-c, No effect with Zinc 15 mg/day
or 30 mg/day
15 mg/day LDL-c, LDL:HDL
126, 131 (n = 126)
30 mg/day (n = 131)
Hooper et al. [52] 1980,
United States
P 5 weeks 8 Males 23-35 Healthy ZnSO4 TG, TC, HDL-c, 25 % reduction of HDL-c. TC, TG,
and LDL-c no significant change.
160 mg/day LDL-c12
Kadhim et al. [20] 2006;
Iraq
DB, P 3 months 15 (Metformin +
Placebo)
Both 40-64 Type-2 Diabetes
patients
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Khan et al. [42], 2013; India R, P 3 months 21 Both 40-69 Type-2 Diabetes
patients
ZnSO4 TG, TC, HDL-c, Decrease in TG. HDL-c increased.
No change in TC and LDL-c.
23 50 mg/day LDL-c
Kim and Lee [21] 2012;
South Korea
P 2 months 20 Females 19-28 Obese Zn gluconate TG, TC, HDL-c No significant change in lipid
parameters
30 mg/day20
Li et al. [28] 2010; China R, DB, P 6.5 months 29 Females 18-55 Obese Multi-vitamin TG, TC, HDL-c, Reduced TC and LDL-c and
increased HDL-c in multivitamin
& mineral supplemented group.
No change in TG.





R, DB, C 3 months 27 Males 35-65 Type-2 ZnSO4 TG, TC, HDL-c, Reduced TC, TG, VLDL-c.
Increased HDL-c
Diabetes patients 100 mg/daya LDL-c, VLDL-c27
Payahoo et al. [26] 2013;
Iran
R, DB, P 1 month 30 Both 18-45 Obese Zn gluconate TG, TC, HDL-c, TG level decreased.
30 30 mg/daya LDL-c No change in other lipid
parameters
Rahimi-Ardabili et al. [27]
2012; Iran
R, DB, P 2 months 30 Both 52.8 ±
12.7
End-Stage Renal ZnSO4 TG, TC, HDL-c, No change in TC, TG and LDL-c.
30 Disease on
Haemodialysis
100 mg/daya LDL-c Increase in HDL
RangaRao et al. [53] 1990;
India
CC 1 month 5 Males NM Type-1 ZnSO4 TG, TC, HDL-c No significant change in lipid
parameters
Diabetes patients 660 mg/daya7
Roozbeh et al. [22] 2009;
Iran





Samman and Roberts [54]
1988; Australia
R, DB, C 1.5 months 41 Both M-28.2
± 2.0
Healthy ZnSO4 TC, LDL- No change in TC. In females LDL-C




150 mg/day c, HDL-c,
HDL2, HDL3
Seet et al. [23] 2011;
Singapore
R, B, P 3 months 20 Males NM Type-2 Zn gluconate TG, TC, HDL-c, No significant change in lipid
parameters
Diabetes patients 240 mg/day LDL-c20




Disease patients 600 mg/daya β-lipoprotein10
Thurnham et al. [55] 1988;
Chiina
R, DB, P 13.5 months 610b Both 35-64 Healthy Zn gluconate TC No significant change
50 mg/d
ALA-α-linolenic acid, B-Single blinded, C-Cross over; CC-Case–control, DB-Double Blinded, F-female, HDL-c-High Density Lipoprotein-Cholesterol, LDL-c-Low Density Lipoprotein-Cholesterol, M-male, MVM- multivitamin/
mineral,NM-Not Mentioned, O- Observational, P-Parallel, R–Randomized, TC-Total Cholesterol, TG-Triglycerides, Age presented as mean ± SD in years where data were available and as age range in other studies













Only 24 studies were included in Meta analysis and the
reasons for exclusion of 8 studies [48–55] are also men-
tioned in Fig. 1.
Description of the studies and Quality assessment
Studies that were included in the meta-analysis are
English-language, human, controlled trials. Out of the
total of 33 Zinc interventions included in meta-analysis,
26 interventions [17–19, 21–23, 26, 27, 33, 35–43] in-
vestigated the effects of Zinc supplementation alone on
plasma lipids while other 7 interventions investigated the
effect of supplementation of Zinc together with other
vitamins and/or minerals. Duration of Zinc supplemen-
tation ranged from 1 month to 6.5 months with the ex-
ception of one long term study in which Zinc was
supplemented for 7.5 years [44]. The dose of elemental
Zinc supplemented in these interventions ranged from
15–240 mg/day (average dose of elemental Zinc per
intervention: 39.3 mg/day). A variety of Zinc anions
were used, including sulfate [17–19, 22, 27, 33, 34, 38,
39, 42, 43, 46], gluconate [21, 23, 26, 35, 36, 40, 41] and
acetate [20, 37] or undefined [28, 44, 45].
In total, 14,515 participants were assigned to a Zinc
intervention or control group. The age range of partic-
ipants was 19–106 years except one study which was
done in children aged 6–10 years. Out of 24 studies, 7
studies (16 interventions) involved healthy partici-
pants. Of the remaining trials, 8 studies were under-
taken in those with type 2 Diabetes, 4 studies in obese
individuals, 3 studies in subjects with end stage renal
failure undergoing haemodialysis, 1 study in gut cancer
patients and 1 study in patients with Ischemic heart
disease. The mean jaded scale score for all trials in-
cluded in meta-analysis was 3.13, out of a maximum
score of 5 and 16 out of 24 studies scored ≥ 3 marks
(Table 2). Two studies that scored zero points were ex-
cluded from the meta-analysis due to poor methodo-
logical quality (Fig. 1) [49, 52].
Effect Zinc supplementation on total cholesterol
Effect of Zinc supplementation on total cholesterol con-
centration was studied in all 24 studies (33 interven-
tions, n = 14515) [17–23, 26–28, 33–46] included in the
meta-analysis. There was a statistically significant reduc-
tion in TC concentration in the Zinc supplemented group.
The pooled mean difference for TC between Zinc supple-
mented and placebo groups from random effects analysis
was −10.92 mg/dl (95 % CI: −15.33, − 6.52; p < 0.0001).
However statistical heterogeneity as indicated by I2 = 83 %
(p < 0.05) of the data prevents the evaluation of a pooled
estimate for TC (Fig. 2 (I)). In the subgroup-analyses, the
group of interventions (26 interventions, n = 1528) in which
Zinc was supplemented alone demonstrated a similar, sta-
tistically significant reduction in TC concentration in
comparison to control groups. The pooled mean differ-
ence for TC between Zinc supplemented and placebo
groups from random effect analysis was −10.72 mg/dl
(95 % CI: −19.01, −1.32; p <0.05) (Fig. 3(I)) and statis-
tical heterogeneity as indicated by I2 = 80 % (p < 0.05).
When studies were grouped by health status, reduction
in TC in comparison to control groups was statistically
significant and was greater in magnitude (−17.02 mg/dl
[95 % CI: −30.52, −3.52; p < 0.05], [I2 = 87, p < 0.05])
among non-healthy participants (18 interventions, n =
866) (Fig. 4 (I)). Zinc supplementation among healthy
participants (15 interventions, n = 13,650) demon-
strated minor but statistically significant reduction in
TC (−1.22 mg/dl [95 % CI: −2.17, −0.26; p < 0.05], [I2 =
0, p >0.05] ) (Fig. 5(I)).
Effect of Zinc supplementation on HDL cholesterol
Twenty one studies (29 interventions, n = 1,694) [17–23,
26–28, 33–42, 46] explored the effect of Zinc supple-
mentation on HDL cholesterol. The forest plot for over-
all analysis of HDL cholesterol (Fig. 2(II)) shows the
pooled mean difference for HDL cholesterol between
Zinc supplemented and placebo groups from random
effect analysis was 2.12 mg/dl (95 % CI: −0.74, 4.98; p =
0.15) and statistical heterogeneity as indicated by I2 = 83 %
(p < 0.05). Also the group of interventions (25 interven-
tions, n = 1,508) employing Zinc supplementation alone
did not demonstrate a statistically significant increase in
HDL-c levels (+0.73 mg/dl, 95 % CI: −2.30, 3.75, p = 0.64)
in subgroup-analysis (Fig. 3(II)). However, as Fig. 4(II)
illustrates Zinc supplementation among non-healthy
participants (16 interventions, n = 785) demonstrated a
considerable and statistically significant increase in HDL-c
(+6.15 mg/dl [95 % CI: 2.38, 9.92; p < 0.05], [I2 = 85, p <
0.05]). In contrast to this Zinc supplementation in healthy
participants (13 interventions, n = 909) demonstrated a
significant reduction in HDL-c (−3 mg/dl [95 % CI: −5.91,
0.10; p < 0.05], [I2 = 45, p < 0.05]) (Fig. 5 (II)).
Effect of Zinc supplementation on LDL cholesterol
There were 17 studies [17–20, 22, 23, 26–28, 33–35,
39–42, 46] (23 interventions, n = 1,455) in which the
effect of Zinc supplementation on LDL cholesterol
was studied. Forest plot for LDL-c (Fig. 2(III)) shows
there is a statistically significant reduction in LDL-c in
Zinc supplemented group. The pooled mean differ-
ence for LDL-c between Zinc supplemented and pla-
cebo group from random effect analysis was −6.87 mg/
dl (95 % CI: −11.16, −2.58; p < 0.001) and the statistical
heterogeneity of the data as indicated by I2 = 31 was
insignificant (p = 0.08). Forest plot for subgroup
analysis (Fig. 3(III)) of LDL-c shows the pooled mean
difference for LDL-c between Zinc alone supplemented
group and placebo groups from random effect analysis
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was −4.78 mg/dl (95 % CI: −9.14, −0.43; p < 0.05) and the
statistically heterogeneity was I2 = 24 (p = 0.17). When the
interventions done in non- healthy participants (14 inter-
ventions, n = 725) were grouped together, Zinc supple-
mentation demonstrated a significant reduction in LDL-c
(−11.25 mg/dl [95 % CI: −16.06, −6.44; p < 0.05], [I2 = 15,
p > 0.05]) and the magnitude of reduction was greater than
that in overall ungrouped analysis (Fig. 4 (III)). In
contrast to this, Zinc supplementation in healthy partici-
pants (9 interventions, n = 730) demonstrated a smaller
and insignificant increase in LDL-c (+1.12 mg/dl [95 %
CI: −3.93, 6.16; p > 0.05], [I2 = 0, p > 0.05]) (Fig. 5 (III)).
Effect of Zinc supplementation on Triglycerides
Effect of Zinc supplementation on Triglyceride concen-
tration was studied in 19 studies (25 interventions, n =
1,503)[17–23, 26–28, 33–35, 39–43, 46] included in
meta analysis. There was a statistically significant reduction
in triglyceride concentration in Zinc supplemented group.
The pooled mean difference for triglyceride between Zinc
supplemented and placebo groups from random effects
analysis was −10.92 mg/dl (95 % CI: −18.56, − 3.28; p <
0.01) in the presence of statistical heterogeneity of the data
as indicated by I2 = 69 % (p < 0.0001) (Fig. 2(IV)). Also sub-
analysis of the group of interventions in which Zinc was










Afkhami-Ardekani et al., 2008 1 0 1 0 N/A 2
Age-Related Eye Disease Study Research
Group, 2002
1 1 0 0 0 2
Black et al., 1988 1 1 1 0 0 3
Bogden et al., 1988 1 1 0 1 0 3
Boukaïba et al., 1993 1 1 1 0 0 3
Brewer et al., 1991 0 0 0 0 0 0
Chevalier et al., 2002 1 1 1 0 0 3
Crouse et al., 1984 1 1 1 0 0 3
Farvid et al., 2004 1 1 1 1 0 4
Federico at al., 2001 1 0 1 0 N/A 2
Feillet-Coudray et al., 2006 1 1 1 0 0 3
Foster et al., 2013 1 1 1 1 1 5
Freeland-Graves et al., 1982 1 1 0 0 0 2
Gatto et al., 1995 1 0 1 0 N/A 2
Gunasekara et al., 2011 1 0 1 1 0 3
Hashemipour et al., 2009 1 1 1 1 0 4
Hercberg et al., 2005 1 1 1 1 1 5
Hininger-Favier et al., 2007 1 1 1 1 1 5
Hooper et al., 1980 0 0 0 0 0 0
Kadhim et al., 2006 0 1 1 N/A 0 2
Khan et al., 2013 1 0 1 0 N/A 2
Kim et al., 2012 0 0 1 0 0 1
Li et al., 2010 1 1 1 1 0 4
Partida-Hernández et al., 2006 1 1 1 0 0 3
Payahoo et al., 2013 1 1 1 1 1 5
Rahimi-Ardabili et al., 2012 1 1 0 0 0 2
RangaRao et al., 1990 0 0 1 0 0 1
Roozbeh et al., 2009 1 1 1 0 1 4
Samman et al., 1988 1 1 1 0 0 3
Seet et al., 2011 1 0 1 0 N/A 2
Shah et al., 1988 1 0 1 0 N/A 2
Thurnham et al., 1988 1 1 0 0 0 2
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supplemented alone (21 interventions, n = 1,317) demon-
strated statistically significant reduction in TG levels in
Zinc supplemented groups in comparison to their controls
(−8.73 mg/dl, 95 % CI: −16.29,-1.17, p < 0.05) and statistical
heterogeneity as indicated by I2 = 64 % (p < 0.0001) (Fig. 3
(IV)). As Fig. 4 (IV) illustrates Zinc supplementation in
non-healthy participants (16 interventions, n = 773) dem-
onstrated a significant reduction in TG levels which was
greater in magnitude than that in ungrouped analysis
(−17.59 mg/dl [95 % CI: −28.80, −6.39; p < 0.05], [I2 = 77, p
< 0.05]). However, Zinc supplementation in healthy
participants (9 interventions, n = 730) did not demonstrate
a significant reduction in TG levels (−2.97 mg/dl [95 %
CI: −9.75, 3.81; p > 0.05], [I2 = 0, p > 0.05]) (Fig. 5 (IV)).
Other significant effects
Gunasekara, et al. reported a significant reduction in
Total cholesterol/HDL ratio from 3.39 to 3.21 (p < 0.05)
after Zinc supplementation [46]. Although not statisti-
cally significant, a study carried out by Brewer, et al. also
reported reduction of this ratio after Zn supplementa-
tion in newly diagnosed female patients with Wilson’s
disease and patients who had received anti copper ther-
apy (both genders)[49]. Zinc supplementation has shown
significant reduction in VLDL cholesterol concentration
in few studies [19, 36]. Studies have shown Zinc supple-
mentation results in cholesterol to shift from HDL3 to
HDL2 causing an increase in HDL2/HDL3 ratio [51, 54].
Discussion
This comprehensive systematic review and meta-analysis
summarize the data from 32 studies involving a total of
14,515 participants. The results of the meta-analysis shows
Zinc supplementation alone causes a significant reduction
in LDL-c concentration (−4.78 mg/dl, p < 0.05) in the
absence of a significant heterogeneity among the studies.
Although there is considerable heterogeneity amongst the
studies, Zinc supplementation alone reported a statistical
significant reduction in serum TC level (−10.72 mg/dl,
p < 0.05, I2 = 80 %) and TG level (−8.73 mg/dl, p < 0.05,
I2 = 64 %). When analyzed by health status, Zinc sup-
plementation reported a significant reduction in TC,
LDL-c and TG levels in non-healthy patients and the
magnitude of reduction was greater than that in overall
analysis. In healthy patients there was a minor but signifi-





Fig. 2 Forest plots showing effect of Zinc supplementation on; (I)
Total cholesterol, (II) HDL cholesterol, (III) LDL cholesterol, (IV)
Triglycerides. a- female, (b)- male, (c)- Zinc supplementation 15
mg/day, (d)- Zinc supplementation 30 mg/day, (e)- Zinc
supplementation 50 mg/day, (f)- Zinc supplementation 75 mg/
day, (g)- Zinc supplementation 100 mg/day, (h)- reference group,
(i)- Lean group, (j)- Sedentary males, (k)- Trained males
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TG were not significant. When consider HDL-c, Zinc
supplementation demonstrated a statistically insignificant
increase in the ungrouped analysis whereas a statistically
significant increase (+6.15 mg/dl) among non-healthy
patients. These findings are in contrast to results from
a previous meta-analysis of randomized controlled trials,
where no beneficial effects of Zinc supplementation were
observed on plasma TC, LDL-c or TG concentrations in
overall, ungrouped analysis or when interventions were
grouped by health status [25]. Zinc supplementation
has demonstrated a significant increase in HDL-c levels
among patients with diabetes mellitus in previous meta-
analyses which also supports our finding [25, 56]. A finding
probably resulting from favorable results demonstrated
in several studies reported since the time of the previous
meta-analysis [17, 21, 28, 33, 42, 46].
Cardiovascular disease is the leading cause of death in
much of the modern world and two major underlying
causes are disorders of lipid metabolism and metabolic
syndrome [57]. Dyslipidemia is the most important risk
factor for atherosclerosis [58]. Atherosclerosis is the
main aetiological factor behind coronary artery disease,
cerebral vascular disease, and peripheral vascular disease
[59]. Within the past decade, clinical trials have demon-
strated that LDL-c reduction reduce the clinical cardiac
events and the arteriographic investigations have dem-
onstrated that LDL-c reduction can significantly reduce
the rate of arteriographically defined disease progression
[60]. A recent systematic review and meta-regression
analysis concluded that simply increasing the level of circu-
lating HDL-c does not reduce the risk of coronary heart
disease events, coronary heart disease deaths, or total death
and results supported reduction in low density lipoprotein
cholesterol as the primary goal for lipid modifying interven-
tions [61]. Each 40 mg/dl reduction in LDL-c concentration
corresponds to 24 % reduction in major cardiovascular
events [62]. Therefore, current meta-analysis demonstrates
that Zinc supplementation alone can reduce major cardio-
vascular events by ~2.9 % by lowering LDL-c concentration
by 4.78 mg/dl and by 6.8 % in non-healthy individuals
by lowering LDL-c by 11.25 mg/dl at an average dose
of ~40 mg/day. However, atorvastatin a well established
drug for hyperlipidaemia has demonstrated 1.8 mmol/l
(69.6 mg/dl) reduction in LDL-c levels at a dose of
10 mg/day in a meta-analysis involving 164 trials [63].
Previous meta-analyses have reported elevated fasting
and non-fasting concentrations of TGs were associated
with increased risk of coronary heart disease, even after
adjustment for HDL-c concentrations [64, 65]. Further-
more three studies between 2007 and 2008 suggested
that raised non-fasting TG was strongly associated with
increasing risk of myocardial infarction, ischaemic heart
disease, ischaemic stroke and all-cause mortality [66–68].
At mild-to-moderately raised triglyceride concentra-
tions (2–10 mmol/l), lipoproteins are small enough to
enter into arterial wall and thus have the potential to
enter into arterial wall and accumulate causing athero-
sclerosis [69, 70]. High TG concentrations are a marker
for raised remnants rich in cholesterol, which can enter into
intima and lead to foam cell formation, atherosclerotic pla-
ques and ultimately cardiovascular disease and increased
mortality [71]. Understanding from genetic studies and
negative results from randomized trials is low HDL-c might
not cause cardiovascular disease as originally thought and
this understanding has now generated an interest in ele-
vated levels of TGs [71]. Therefore Zinc supplementation
could reduce the cardiovascular events and deaths, as it re-
sults in significant reduction in TC, TG and LDL-c.
Dyslipidemia is one of the major risk factors for cardio-
vascular disease in diabetes mellitus. High plasma TG,
increased small dense LDL-c particles, low HDL-c are
characteristic features of diabetic dyslipidemia and
these lipid changes are mainly attributed to increased
free fatty acid flux secondary to insulin resistance [72].
The increase in cardiovascular risk in obesity depends
to a significant extent on changes in lipid profile, mainly
decreased HDL-c and increased TG and insulin resistance
is the central cause for these changes [73]. Prominent and
known risk factors that contribute to the increased in-
cidence of atherosclerosis in hemodialysis patients are
disorders in lipoprotein metabolism and elevated plasma fi-
brinogen concentrations [74]. Therefore the participants we
categorized as non-healthy (patients with - type 2 diabetes,
End stage renal failure and on haemodialysis and obesity)
are at increased risk of dyslipidemias. Zinc supplementation
significantly reduces TC, LDL-c and TG and elevates
HDL-c in non-healthy patients. Elevated plasma con-
centrations of HDL-c are associated with protection from
atherosclerotic cardiovascular disease. Cardio protective
effect of HDL-c is due to its role in reverse cholesterol
transport in which cholesterol from peripheral tissues is
returned to the liver for excretion in the bile, its protective
effect on endothelial cells and its antioxidant activity [75].
All these evidence support that Zinc supplementation
will effectively reduce the cardiovascular risk among
non-healthy patients.
(See figure on previous page.)
Fig. 3 Forest plots showing effect of Zinc supplementation alone (sub-analysis) on; (I) Total cholesterol, (II) HDL cholesterol, (III) LDL cholesterol,
IV Triglycerides. (a)- female, (b)- male, (c)- Zinc supplementation 15 mg/day, (d)- Zinc supplementation 30 mg/day, (e)- Zinc supplementation
50 mg/day, (f)- Zinc supplementation 75 mg/day, (g)- Zinc supplementation 100 mg/day, (h)- reference group, (i)- Lean group, (j)- Sedentary
males, (k)- Trained males





Fig. 4 Forest plots showing effect of Zinc supplementation in non-healthy participants on; (I) Total cholesterol, (II) HDL cholesterol, (III) LDL cholesterol,
(IV) Triglycerides





Fig. 5 Forest plots showing effect of Zinc supplementation in healthy participants on; (I) Total cholesterol, (II) HDL cholesterol, (III) LDL
cholesterol, (IV) Triglycerides
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Our results demonstrated HDL-c concentration was
significantly reduced due to Zinc supplementation among
healthy participants. A previous meta-analysis also showed
that Zinc supplementation among healthy individuals was
associated with a significant reduction in HDL-c concen-
tration supporting our finding [25]. Low HDL-c (=/<
40 mg/dl) is one of the 5 major Coronary Heart Disease
(CHD) risk factors, and HDL-c level is also a component
of the Framingham scoring system, the method used to es-
timate 10-year CHD risk and determine the intensity of
lipid-lowering therapy [75]. Furthermore Zinc supplemen-
tation did not demonstrate a significant reduction in LDL-c
or in TG despite a minor reduction in TC. Therefore Zinc
supplementation may not have much beneficial effects in
healthy people.
Several molecular mechanisms are believed to be in-
volved in reduction in serum lipid levels following Zinc
supplementation. In Zinc-deficient rats lowered plasma
HDL-c and some apoproteins (A1, A2, C and E) but also
elevated total cholesterol concentrations have been ob-
served [76, 77]. On the other hand, Zinc supplementa-
tion has been shown to inhibit the development of
atherosclerosis in rabbits fed a high cholesterol diet [78].
It is well documented that Zinc is an important mediator
of insulin storage and secretion from the pancreas [78].
In addition, pancreatic beta-cells utilize a very efficient
transporter (ZnT8) to accumulate Zinc inside the cells.
Thus, Zinc deficiency or alterations in ZnT8 expression
have a potential to depress insulin secretion [79]. Zinc
enhances the phosphorylation of insulin-receptor substrates
to activate a series of signal transduction, improving insulin
sensitivity [80, 81]. Insulin resistance at the adipocytes re-
sults in increased release of fatty acids into the circulation
and then increased free fatty acid flux to the liver stimulates
the assembly and secretion of VLDL resulting in hypertri-
glyceridemia [82]. Zinc supplementation either improving
insulin secretion or reducing insulin resistance as described
above inhibits the lipolysis in adipose tissues, reduce free
fatty acid release into the circulation and its availability to
the liver and excessive lipoprotein synthesis. Besides Zinc
contribution to insulin secretion and action, Zinc directly
affects lipid metabolism. Recently it has been shown
that Zinc deficiency down regulates fatty acid utilization in
mitochondria and peroxisomes and up regulates lipid
synthesis in the rat liver affecting the expression of
genes encoding enzymes contributing to liver lipid
homeostasis [83].
The present meta-analysis has notable strengths. These
include 1) large number of individuals in the sub group
analysis in which the effect of Zinc alone supplementation
was studied (n = 1,528), 2) studies were assessed using
jaded scale score and the studies with poor methodo-
logical quality were excluded from meta-analysis, 3) use of
random effect model of meta-analysis which allow
heterogeneity among studies and 4) average dose of elem-
ental Zinc used in the interventions included in meta-
analysis (39.3 mg/d) does not exceed the tolerable upper
intake level (40 mg elemental Zinc per day in adults)
[84]. A limitation of present meta analysis was presence
of considerale heterogeneity when assessing the effect
of Zinc supplementation on TC anc TG concentrations
which stems from; a) Variations in baseline parameters
such as serum Zinc status and lipid levels, b) Differences
in Zinc doses, formulae, sample sizes and study durations,
and c) Limited availability of data on Zinc intake from
other sources such as diet.
Conclusions
The present meta-analysis demonstrates that Zinc sup-
plementation has favourable effects on plasma lipid
parameters. Zinc supplementation significantly reduced
total cholesterol, LDL cholesterol and triglycerides. In
addition to that, Zinc supplementation in non-healthy
patients demonstrated a significant elevation of HDL
cholesterol. Therefore it may have the potential to reduce
the incidence of atherosclerosis related morbidity and
mortality especially in non-healthy patients who are at
risk of atherosclerosis.
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